Premium
RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY)
Author(s) -
Gibb A.,
Pirrie S.,
Linton K.,
Paterson K.,
Davies A.,
Collins G.,
Menne T.,
McKay P.,
Fields P.,
Miall F.,
Nagy E.,
Wheatley K.,
Warbey V.,
Barrington S.,
Radford J.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_68
Subject(s) - brentuximab vedotin , medicine , tolerability , oncology , refractory (planetary science) , surgery , gastroenterology , lymphoma , adverse effect , hodgkin lymphoma , physics , astrobiology